There is a paucity of data about the impact of systemic statins on vitiliginous lesions in non‐
segmental vitiligo (NSV) patients. To the best of our knowledge, no other studies have …

Lipid lowering therapy in 2022 and beyond - How far we have come Lipid lowering therapy in
2022 and beyond - How far we have come Prog Cardiovasc Dis. 2022 Nov-Dec:75:1-3. doi …

Objectives: Identify and appropriately diagnose stable angina. Understand pathophysiology
behind myocardial ischemia to assist in treatment options. Identify and manage risk factors …

Background An inverse association between lipoprotein (a)(Lp [a]) and type 2 diabetes
mellitus is well documented. However, data on the association of the metabolic syndrome …

Combinations of lipid-lowering agents can often bring LDL cholesterol down to around 40
mg/dL (1 mmol/L). Randomized controlled trials indicate that this reduces the risk of …

Abstract Purpose of Review Given the increasing burden of cardiovascular disease, we
review the literature for earlier initiation of statin therapy at younger ages and lower low …

Background Proprotein convertase subtilisin/kexin type 9 inhibitors, such as evolocumab,
are cholesterol-lowering drugs effective in lowering lipid levels in high-risk patients with …

Methods Online databases were searched for randomized controlled trails (RCTs)
evaluating NASH treatments in biopsy-proven NASH patients. Treatments were classified …

Objective Populations with knee osteoarthritis (KOA) are at increased risk of cardiovascular
disease, due to higher prevalence of risk factors including dyslipidaemia, where statins are …

Coronary artery disease (CAD) risk increases in proportion to the magnitude and duration of
exposure to plasma low-density lipoprotein cholesterol (LDL-C), doubling every additional …